Condition: Prion Disease · Sponsor: Ionis Pharmaceuticals, Inc.
The purpose of this study is to evaluate the safety, tolerability, pharmacokinetics and pharmacodynamics of intrathecal (IT) delivery of ION717.
This description comes directly from the study's public registry record.
Ionis Pharmaceuticals, Inc. · (844) 892-5665 · PrionDisease@clinicaltrialmedia.com
Always discuss trial participation with your own doctor first.
| Massachusetts General Hospital | Boston, Massachusetts, United States | Recruiting |
| NYU Langone Health | New York, New York, United States | Recruiting |
| University Hospitals Cleveland Medical Center | Cleveland, Ohio, United States | Recruiting |
| Royal Melbourne Hospital | Parkville, Australia | Recruiting |
| McGill University Health Centre | Montreal, Quebec, Canada | Active Not Recruiting |
| Hôpital Universitaire Pitié Salpêtrière | Paris, France | Recruiting |
| University Medical Center Göttingen | Göttingen, Germany | Recruiting |
| Tel Aviv Sourasky Medical Center | Tel Aviv, Israel | Recruiting |
| Fondazione I.R.C.C.S. Istituto Neurologico Carlo Besta | Milan, Italy | Recruiting |
| Mihara Memorial Hospital | Gunma, Isesaki-shi, Japan | Active Not Recruiting |
| National Center of Neurology and Psychiatry | Tokyo, Kodaira-shi, Japan | Recruiting |
| Neuromuscular Center Yoshimizu Hospital | Yamaguchi, Shimonoseki-shi, Japan | Recruiting |
+ 1 more locations — full list on the registry record.
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT06153966